Production (Stage)
Appili Therapeutics Inc.
APLIF
$0.0137
$0.001916.10%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -111.37% | 2,176.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -111.37% | 2,176.47% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -111.37% | 2,176.47% | |||
| SG&A Expenses | 115.44% | -32.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.26% | -21.88% | |||
| Operating Income | -19.82% | 25.65% | |||
| Income Before Tax | 146.69% | 29.87% | |||
| Income Tax Expenses | 371.83% | -888.89% | |||
| Earnings from Continuing Operations | 142.42% | 31.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 142.42% | 31.28% | |||
| EBIT | -19.82% | 25.65% | |||
| EBITDA | -19.90% | 25.72% | |||
| EPS Basic | 141.94% | 31.11% | |||
| Normalized Basic EPS | 145.00% | 28.57% | |||
| EPS Diluted | 141.94% | 31.11% | |||
| Normalized Diluted EPS | 145.00% | 28.57% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||